Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LGMN | Q99538 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17305269 | 0.87 | NPSR1 (0.52) | HTTTP53MAPTTSHRLGMN | |
| SCHEMBL20522647 | 0.86 | ALDH1A1 (0.53) | HTTTP53MAPTTSHRLGMN | |
| SCHEMBL19078350 | 0.85 | STS (0.46) | HTTTP53GPR119TSHRLGMN | |
| SCHEMBL19078363 | 0.85 | ALDH1A1 (0.47) | HTTTP53MAPTGPR119TSHR | |
| SCHEMBL17305322 | 0.84 | GPR119 (0.48) | HTTTP53GPR119TSHRLGMN | |
| SCHEMBL17305273 | 0.84 | GPR119 (0.49) | TP53MAPTGPR119LGMNKMT2A | |
| SCHEMBL22539564 | 0.81 | STS (0.46) | TP53GPR119LGMNKMT2AALDH1A1 | |
| SCHEMBL25330636 | 0.80 | LGMN (0.53) | TP53MAPTGPR119LGMNKMT2A | |
| SCHEMBL17305361 | 0.80 | MAPT (0.51) | HTTTP53MAPTGPR119PARP10 | |
| SCHEMBL17305315 | 0.78 | LGMN (0.45) | HTTTP53MAPTTSHRLGMN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981960-B2 | Pyrrolidine compound and application as melanocortin receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9981960-B2 | Pyrrolidine compound and application as melanocortin receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
| WO-2015182723-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | 田辺三菱製薬株式会社 | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MC1R, MC5R, MC3R | HTT 1941/4885TP53 4769/4885MAPT 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.